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INTRODUCTION
Tuberculosis is an infectious disease producing a major global health
problem worldwide. The incidence rate of tuberculosis in India is very high
and accounts for one third of global cases . Annually about 8 million
individuals around the world develop TB and 70,000 of these patients acquire
TB meningitis . In immune competent individuals, CNS tuberculosis accounts
for about 1% of all cases of tuberculosis and 6% of extra pulmonary
tuberculosis1 .
The occurrence of neurotuberculosis goes hand in hand with the
incidence of TB infection in the general population . Ten percentage of all
patients with tuberculosis have been estimated to have CNS involvement2. The
various manifestations of neurotuberculosis is included under three major
clinical categories: meningitis, tuberculoma brain, spinal tuberculous
arachnoiditis.
The Revised National Tuberculosis Control Programme (RNTCP) of
Government of India based on universally recommended ‘directly observed
treatment short-course’ (DOTS) therapy was launched in 1997. DOTS therapy
in tuberculosis is the standardized treatment of TB patients in India.
RNTCP is the largest and the fastest expanding programme in the world .In
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India more than 11 million patients have been treated since the inception of
the RNTCP 3.
There is no gold standard for the diagnosis of neurotuberculosis unlike
pulmonary tuberculosis .This lays an obstacle in diagnosis and management .
Very few published data regarding the efficacy of the RNTCP strategy in
management of the spectrum of neurotuberculosis exist. Documenting the
efficacy of these standardized regimens in the management of neurological
TB will be of additional value to the available existing evidence . The present
study prospectively assesses the treatment outcomes in patients with various
forms of neurological TB who receive the standardized RNTCP treatment
regimens.
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REVIEW OF LITERATURE.
CNS manifestations of tuberculosis primarily include three clinical
categories: meningitis, tuberculoma brain, spinal tuberulous arachnoiditis and
the less common clinicopathological entity of TB abscess.
Classification of neurological tuberculosis 4
Tuberculosis meningitis
Tuberculosis arachnoiditis
Basal
Opticochiasmatic
Spinal
Tuberculoma
Intracranial
Spinal
Tuberculosis abscess
Tuberculosis meningitis
TBM is inflammation of meninges that surrounds the brain due to
infection with mycobacterium tuberculosis . It accounts for 70- 80 % of cases
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of neurological TB 5,6. Though it forms the major bulk of neurotuberculosis
there is often a delay in the diagnosis and institution of specific therapy for
TBM. Early institution of therapy is considered the single most important
factor which influences the outcome and development of serious
neurological sequelae.
Pathogenesis of CNS tuberculosis
Mycobacterium tuberculosis is the pathogenic organism in causation of
tuberculous meningitis by means of haematogenous spread secondary to
disease elsewhere in the body. Primary tuberculous infection is associated
with bacteremia which will form Rich ‘s focus in the meninges, parenchyma
of the brain or the spinal cord , sub-pial and sub- ependymal surface.. Rich’s
focus remains silent for many years after the primary infection . Rupture of the
lesion results in meningitis ,and growth of the lesion produces
tuberculoma7. Depending on the number , virulence and immune response of
the host, the type and extent of the lesion varies.
The 3 main pathologic features in tuberculous meningitis are:
inflammatory meningeal exudates ; vasculitis of the arteries traversing the
exudate, mainly small and medium-sized vessels; and disturbance of the flow
of the cerebrospinal fluid 8. These basal exudates are more severe around the
circle of Willis 9 . Vessels traversing the exudates are mainly affected .They
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produce vessel wall inflammation , narrowing and occlusion of the vessel by
thrombus. Tuberculous vasculitis predominantly affect the deep penetrating
branches [lenticulostriate, medial striate, thalamo perforating branches] and
produce infarcts in the basal ganglia and thalamus1 0 . Large vessels like ICA
and proximal MCA are also affected .Obstruction to CSF flow at the level of
basal cisterns will produce hydrocephalus11.
CLINICAL FEATURES
Tuberculous meningitis presents itself in 3 stages 11.The clinical
manifestation depends on the stage of illness. The early prodromal phase
consists of non specific symptoms such as apathy, anorexia, nausea,
vomiting, restlessness, behavioral changes which occurs 2- 8 weeks prior to
the meningitic phase. The meningitic phase is characterized by headache,
vomiting and fever. Neck stiffness is generally not as severe as pyogenic
meningitis. In infants, tense fontanelle is a more important sign than neck
stiffness. In third stage, raised ICT will dominate the clinical picture and is
characterized by altered sensorium, deterioration in vision, pupillary dilatation
and pyramidal signs .
Persistent low grade evening rise of temperature is a prominent feature
in about 80% of patients. A past history of primary pulmonary tuberculosis is
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present in approximately 50% of children with tuberculous meningitis and
10% of adult patients.12,13,14
Tuberculous meningitis in addition to causing non specific symptoms
also causes Cranial nerve palsies in 20–30% of patients . In patients who
ignore the intial vague symptoms the cranial nerve palsy may be the initial
presenting manifestation. Among the cranial nerves sixth nerve is most
commonly affected. Impairment of vision in TBM may be due to
optochiasmatic arachanoiditis , third ventricular compression of optic
chiasma (if hydrocephalus develops), optic nerve granuloma, and ethambutol
toxicity.
Fundus examination may reveal pappiledema and choroid tubercles .
Choroid tubercles as such are very rare , and they are found in patients with
TBM associated with military tuberculosis.Only in 10 % of patients such
tubercles are found in patients with TBM not associated with military
tuberculosis15.
During the course of the illness patients may develop hemiplegia due to
infarction secondary to vasculitis . At times, abnormal movements such as
chorea , hemiballism ,generalized tremors, myoclonic jerks and ataxia have
been observed in children . Seizures, either focal or generalised, may occur
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during acute illness or months after treatment.15As the disease progresses,
increasing evidence of cerebral dysfunction sets in.Apathy and irritability tend
to progress to increasing lethargy, confusion, stupor and coma. The terminal
illness is characterised by deep coma, decerebrate or decorticate rigidity, and
spasm.
Clinical staging system for tuberculosis meningitis50 51
Stage I : patient fully conscious and oriented with signs of
meningism but no focal signs and no evidence of
hydrocephalus;
Stage II : patient is confused and/or with focal signs such as squint
And hemiparesis; And
Stage III : patient having stupor, delirium or coma with complete
Hemiplegia or paraplegia.
DIAGNOSIS
Cerebrospinal fluid analysis is pivotal in diagnosing tuberculous
meningitis. The abnormalities found in CSF of patients with tuberculous
meningitis is a predominant lymphocytic pleocytosis (60–400 white cells per
ml) with increased protein levels (0.8–4 g/l) . Polymorphonuclear cells may
be observed in the early stages of infection ,which are later replaced by
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lymphocytes over the course of several days to weeks . Following initiation
of treatment with ATT a paradoxical increase in polymorphonuclear cells
or lymphocytes was observed by Sutlas16.
In elderly immunocompetent patients CSF appears to be normal or
acellular. Normal or acellular CSF appears to be more common in the elderly
patient (greater than 60 years of age), even in the absence of concomitant HIV
infection (Karstaedt et al 1998) . The Opening pressure is usually elevated.
Two studies done by Ogawa et al 18 and Leiguarda et al 19showed that
approximately half of both adult and pediatric patients having normal opening
pressures.
The CSF sugar values are less than half the serum glucose values. The
values may range between 18–45 mg/dl.A negative cytology for malignant cells in
the CSF is essential for the diagnosis of TBM. On allowing the CSF to stand, a fine
clot resembling a pellicle or cobweb may form. The appearance of the faintly
visible "spider's web clot" is due to the very high level of protein 20 in the CSF
(ie, 1-8 g/L, or 1000-8000 mg/dL).
The gold standard is to document the presence of the tubercle bacilli in
the CSF, either by smear examination or by bacterial culture. The yield is high
when the ventricular fluid is examined and also by centrifuging the CSF
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fluid. The rates of positivity for clinically diagnosed cases range from 25% to
70% and the time duration required for culturing the mycobacterium bacilli is
prolonged ( several weeks ). Due to the inherent difficulties with CSF culture ,
a number of tests have been developed to establish an early and definitive
diagnosis.
Polymerase chain reaction is the best diagnostic technique for
diagnosing mycobacterial infection . In Kox et al study the sensitivity of CSF
polymerase chain reaction has not exceed 50%21 . Polymerase chain reaction is
becoming increasingly available, and may remain positive 4 or more weeks
after the initiation of treatment 22. Nested polymerase chain reaction which
depends on the method for extracting DNA and the amount of DNA in the
sample which are crucial in determining the sensitivity 23 . MPB 64 protein
encoding gene is most specific for diagnosis of tuberculous meningitis24 .
Though radioactive bromide partition testing and identification of cell
wall components (eg, tuberculostearic acid) were reported to have a
sensitivity and specificity over 90%. These test were not of clinical utility.
Antibodies against tubercle bacilli can be detected with enzyme-linked
immunosorbent assay (ELISA)
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The tuberculin test:
A negative tuberculin skin test does not rule out tuberculosis.
Tuberculin skin test should not be offered to a patient unless there is a plan to
start treatment in event of a positive skin test 25.
IMAGING
Imaging reveals basal enhancement of the meninges (particularly in the
perimesencephalic cisterns ), hydrocephalus, infarction edema often located
periventricularly, and mass lesions due to associated tuberculoma or
tuberculous abscess26 27 . A study revealed that hydrocephalus was the
single most common abnormality seen by CT scan in 52 % to 80% of patients
with tuberculous meningitis28 29 .The degree of hydrocephalus correlates with
the duration of the disease30 .The next common imaging feature was
enhancement of the meninges is seen in approximately 60% of patients with
tuberculous meningitis which may be localized or diffuse 31(Goyal et al 1997).
Tuberculous pachymeningitis should also be considered in the differential
diagnosis of "idiopathic" cranial hypertrophic pachymeningitis(Parney et al
1997)32
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In children, plain CT showing enhancement in the the basal cisterns has
been reported to be a specific sign for tuberculous meningitis (Andronikou
2004)33.
The third common finding on imaging is infarctions. The majority of
infarcts are located in the basal ganglia, internal capsule, thalamus and rare in
the large vessel territories.Contrast CT and MRI are superior in
demonstratingthe abnormalities than plain CT. Infarction secondary to
vasculitis are seen in thalamic, basal ganglion, and internal capsule
regions.This occurs due to thrombosis in vessels traversing the
perimesencephalic cistern. The basilar exudates are thick and they enhance
intensely in the basal cisterns (spider-leg appearance ) and in the sylvian
fissures. The diffusion weighted images are more sensitive than the
conventional MRI , in depicting early ischemic lesions. Two large
community based studies analysed the imaging findings in patients with
TBM and found that hydrocephalus was found in 78% basal enhancement
was found in 38% infarcts in 15-30% and tuberculomas in 5-10% of the
patients.
Tuberculomas are nothing but enlarged rich’s focus lesions which
appear as low- or high-density and rounded or lobulated masses and show
intense homogenous or ring enhancement after contrast administration. The
distinctive features of tuberculoma are the irregular wall of varying thickness ,
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moderate to marked perilesional oedema. The caseating granulomas are
distinctive from the non caseating granuloma .Noncaseating granulomas are
homogeneously enhancing lesions. Caseating granulomas are rim enhancing; if
these have a central calcific focus, they may form a targetlike lesion34.
Granulomas may also form a miliary pattern with multiple tiny nodules
scattered throughout the brain .Tuberculomas are infrequently seen on CT or
MRI of patients with tuberculous meningitis. All lesions are surrounded by
hypoattenuating edema .Tuberculomas may be single or multiple and are more
common in frontal and parietal lobes, usually in parasagittal areas. On CT
scanning35, tuberculomas measure more than 20 mm in diameter, frequently
irregular in outline, and are always associated with marked cerebral oedema
(leading to midline shift) and progressive focal neurological deficit.The MRI
features of tuberculoma depend on whether the lesion is non-caseating,
caseating with a solid centre, or caseating with a liquid centre.
The non-caseating granulomas36 are hypointense on T1-weighted
images and hyperintense on T2-weighted images; after contrast administration
the lesion usually shows homogenous enhancement.The second type of
tuberculomas are hypointense or isointense on T1-weighted images and also
on T2-weighted image. After contrast administration there is ring
enhancement. These types of granuloma have variable degree of perilesional
oedema. The tuberculoma with central liquefaction of the caseous material
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appears centrally hypointense on T1- and hyperintense on T2-weighted images
with a peripheral hypointense ring which represents the capsule of
tuberculoma . Images after contrast administration show ring enhancement.MR
spectroscopy with a single-voxel proton technique can be used to characterize
tuberculomas and differentiate them from neoplasms. Tuberculomas show
elevated lipid peak that are best seen by using the stimulated-echo acquisition
mode technique and a short echo time. The carotid or MR angiogram shows
changes in vessels of the circle of Willis. These changes include uniform
narrowing of large segments, small segmental narrowing, irregular beaded
appearance and complete occlusion.
These vascular changes are due to either vasculitis or mechanical
compression by the basilar exudate .
Chest radiograph
The chest radiographs reveal findings suggestive of pulmonary TB in
25%-50% of adult patients and 50 to 90 per cent of children with TBM seen in
western countries
Diagnosis of Neurological TB
The diagnosis of TBM was established as perAhuja et al 37 criteria.
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Criteria for the diagnosis of TB meningitis
A. Clinical
(i) fever and headache lasting for more than 14 days (mandatory)
(ii)vomiting, alteration of sensorium or focal deficit (optional)
B. Cerebrospinal fluid
(i) pleocytosis with more than 20 cells, predominantly (greater than 60%)
lymphocytes
(ii)protein greater than 100 mg/dL, sugar less than 60% of corresponding
blood Sugars
(iii) negative India ink studies and cytology for malignant cells (in
relevant situations)
C. Radiological
CT studies of the head showing 2 or more of the following:
(i) exudates in basal cisterns or in Sylvian fissures
(ii)hydrocephalus
(iii) infarcts
(iv) gyral enhancement
D. Evidence of extra-neural tuberculosis
Active tuberculosis of lungs, gastrointestinal tract, urogenital tract,
lymph nodes, skeletal system or skin as evidenced by appropriate
radiological or microbiological tests or by the presence of caseation necrosis
on histopathological examination
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The 4 sub-criteria described above have been incorporated into 4 groups in
descending order of sensitivity:
1. Definite tuberculosis meningitis: (i) clinical criteria (A); (ii) bacterial
isolation from CSF or diagnosis at autopsy
2. Highly probable tuberculosis meningitis
(i) Clinical criteria (A); (ii) All 3 of(B) and (C) and (D); and good response to
antituberculosis treatment
3. Probable tuberculosis meningitis
(i) Clinical criteria (A); (ii) Any 2 of B, C and D
4. Possible tuberculosis meningitis
(i) Clinical criteria (A); (ii) Any one of (B) (C) and (D)
INTRACRANIAL TUBERCULOMAS
Definition
Tuberculoma is a mass of granulation tissue made up of a
conglomeration of microscopic small tubercles. Macroscopically a typical
tuberculoma is a well defined grayish avascular mass with a yellow
caseating core. Histologically the central necrotic core is surrounded
bytuberculous granulation tissue containing epitheliod cells , lymphocytes
and langhans giant cells. Surrounding the tuberculoma there may be arterites,
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neuronal damage and edema of varying degree of severity . As the
tuberculoma regresses there is increasing collagen formation , sometimes
associated with deposition of calcium salts.Tubercle bacilli can be found in
majority of surgical specimens or autopsy specimens, but in their absence the
pathological diagnosis can made on the histological appearance of the
granuloma alone41. In most cases lesions are solitary but in 15- 34 % of cases
multiple tuberculoma are found42.
CLINICAL FEATURES
Most often patients present with signs and symptoms of space
occupying lesions . Compared with other space occupying lesions the
incidence of convulsions is high as much as 85%43 . Fever and ill health are
unusual findings , but a past history of tuberculosis or a evidence of active
tuberculosis outside the CNS occurs in about 50% of the patients41. 60- 70%
of intracranial tuberculoma present with seizures. 56 – 93 % have features of
raised intracranial pressure. 33- 68% have focal neurological defecit. Gulati
et al found the commonest cause of focal seizures is tuberculoma42.A single
confluent large granuloma with necrotic centre63 – 73 % of patients.
Tuberculomas may also be multiple.
In the early phase of the illness edema, necrosis may appear as low
attenuating areas on CT scan. Once the granuloma starts to organize there
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may be high attenution , contrast enhancement and calcification as well as
ring enhancement with variable degree of surrounding edema.
Criteria for the diagnosis of tuberculoma
Clinical
(i) the presence of clinical evidence of raised intracranial pressure (ICP)
with headache and vomiting and/or papilloedema
(ii)the presence of progressive focal neurological deficit (motor or
sensory)
CT features
(i) the size of the lesion (largest dimension) > 20 mm
(ii)irregular shape of the lesion
(iii) the presence or absence of a midline shift as evidenced by the shift
of any one of the midline structures, namely the interhemispheric
fissure, septum pellucidum, or the third ventricle
Response to antituberculosis treatment
(i) Good clinical and radiological response to antituberculosis treatment
TUBERCULOSIS RADICULOMYELITIS (TBRM)
Tuberculosis radiculomyelitis is a form of spinal TB and may develop in
one of the three ways: [i] as a primary TB lesion; [ii] TBM extending
downwards [iii] an extension from vertebral TB . TBRM includes cases
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designated as arachnoiditis, intradural spinal tuberculoma or granuloma and
spinal cord complications of TBM.
Treatment
Antituberculosis treatment is the main stay for the treatment of
neurological TB.The absence of a gold standard diagnostic test is the main
hurdle in the management of neurotuberculosis. There should neither be a
delay or nor injudicious usage of ATT as it is potentially toxic and is required
for a long period. Diagnosis by either by PCR or by immunological methods
is seldom possible in every case, because of the limited facilities. A CSF study
is mandatory if there is no contraindication for a lumbar puncture. If suspicion
of TBM is high then anti tuberculosis treatment should be initiated at the
earliest. The pros and cons of initiating anti tuberculosis treatment before the
confirmation of the diagnosis should be carefully weighed in each patient.
However, the most important principle of therapy is that anti tuberculosis
treatment should be initiated when the disease is suspected. It should not be
delayed until proof of diagnosis of TBM has been obtained.
Treatment regimens
There are no convincing randomized, controlled clinical trials to
suggest that any particular regimen is superior in the treatment of TBM. The
recommended drugs are isoniazid, rifampicin, pyrazinamide and ethambutol
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or streptomycin. Ethambutol is preferred over streptomycin because of its
better CSF penetration. The British Infection Society recommends 4 drugs
(isoniazid, rifampicin, pyrazinamide, and ethambutol) for 2 months followed
by 2 drugs (isoniazid and rifampicin) for at least 10 months45 for all forms
ofneurotuberculosis. The drugs exhibit differences in CNS penetration
Isoniazid, pyrazinamide, and ethionamide penetrate readily into cerebrospinal
fluid, whereas rifampin, ethambutol, and streptomycin do so poorly,
especially in noninflamed meninges.46 Penetration through inflamed
meninges is excellent, with CSF concentration 90% that of serum; however,
in the absence of inflammation the penetration is about 20% of serum levels .
Drug toxicity with isoniazid includes hepatotoxicity, peripheral neuropathy
when pyridoxine is not co-administered, seizures, alterations in mental state,
and potentiates phenytoin toxicity. Rifampin, a bactericidal against
intracellular and extracellular bacilli, achieves high serum levels after oral
administration. Cerebrospinal fluid levels are approximately 20%, or less, of
serum levels in the presence of meningeal inflammation. Pyrazinamide has its
bacteriostatic effect on intracellular rather than extracellular organisms and
penetrates the CSF well. Some have shown cerebrospinal concentrations of
100% of the serum concentration.In the presence of meningeal inflammation
ethambutol achieves CSF concentrations of 10% to 50% of serum levels. The
chief toxicity of this tuberculostatic drug is retrobulbar neuritis, which
develops in as many as 1% of persons on the currently recommended dose.
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Careful attention to visual acuity and color perception is required while the
patient is on this drug. Streptomycin penetration into cerebrospinal fluid
requires meningeal inflammation for levels to approximate one quarter of that
of the serum . Streptomycin must be given parenterally, and renal failure and
ototoxicity are its chief adverse effects.
ROLE OF STEROIDS IN TUBERCULOUS MENINGITES:
Steroids reduce the inflammation and the neurological complications
,thus enhancing Recovery38.Adjunctive glucocorticoid therapy is beneficial in
both adults and children with tuberculous meningitis39.The benefit was most
evident for patients with early disease. The adverse reactions due to usage of
steroids include gastrointestinal bleeding, infections hyperglycaemia,
osteoporosis and neutropenia .Glucocorticoid regimen40 followed is either
dexamethasone or prednisone. Dexamethasone is used with a total dose of 8
mg/day for children weighing <25 kg; 12 mg/day for adults and children >25
kg, for 3 weeks, then tapered off gradually over the following 3 to 4
weeks.Prednisone is used with a dose of 2 to 4 mg/kg per day for children; 60
mg/day for adults, for 3 weeks, then tapered off gradually over the following 3
weeks.
Surgical intervention is required in the management of obstructive
hydrocephalus, although in the absence of obstruction hydrocephalus may be
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managed medically. When reducing elevated intracranial pressure in the latter
instance, the use of furosemide and acetazolamide was significantly more
effective than antituberculous drugs alone47. Although a ventricular drain is
helpful in the acute stages, ventriculoperitoneal and ventriculoatrial shunts are
effective and should not be delayed until the infection is eradicated. Surgery
may also be necessary in the face of tuberculomas or tuberculous abscesses
developing in tandem with tuberculous meningitis. However, tuberculomas
often resolve with adequate therapy, and unless there is impending cerebral
herniation or compromise of the anterior visual pathways, the procedure may
prove unnecessary.
Surgery is also mandated when the diagnosis of a CNS tuberculoma is
in doubt. Some investigators recommend medical trials of antituberculous
medication for a duration of at least 2 months before resorting to surgical
exploration in suspected cases 48. Paradoxical progression of CNS
tuberculosis with the appearance of new lesions on radiographic imaging may
occur immediately after the institution of appropriate treatment 49. Similarly,
2 to 18 months after the initiation of adequate antituberculous therapy,
enlarging intracranial tuberculomas may result in clinical deterioration. Teoh
and Humphries found that the organisms isolated from these enlarging
tuberculomas were sensitive to the antibiotic employed and suggested that
their appearance was an immunological phenomenon50. Surgery can usually
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be avoided with the administration of corticosteroids and continued
antituberculous therapy. Resolution of the fever may require weeks. CSF
glucose levels return to normal within 2 months in 50% of patients and within
6 months in almost all, whereas the CSF pleocytosis requires more than 6
months to resolve in 25% and the CSF protein remains elevated in 40% at
this time 51. Additionally, the continued alteration in level of consciousness in
the early stages of the disease may be the result of concomitant
hydrocephalus or hyponatremia.
A study of tuberculous meningitis in inner-city Atlanta revealed a
mortality rate of 41.2% despite the initiation of appropriate therapy within 3
days of hospital admission. . A large study from Vietnam reported that survival
of tuberculous meningitis is substantially worse in the HIV-infected population
(Thwaites et al 2005). Whereas the clinical manifestations were not different
between the HIV-infected and non-infected groups, mortality at 9 months was
64.6% in the former and 28.2% in the latter45(Thwaites et al 2005). The
sequelae include cognitive disturbances, seizures, hemiparesis, ataxia, visual
impairment accompanying optic atrophy, and other persistent cranial nerve
palsies 53, 54
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AIMS AND OBJECTIVES
1) To study the clinical spectrum of neurotuberculosis.
2) To prospectively study the treatment outcomes in patients with various
forms of neurotuberculosis being treated with the standardized
RNTCP DOTS regimen.
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MATERIALS AND METHODS
Patients diagnosed to have neurotuberculosis in Rajiv Ghandhi Govt.
General Hospital during the period January 2012 to December 2012 were
prospectively studied . Patients were enrolled from Neurological services
from RGGGH .
Diagnosis of Neurological TB
The diagnosis of TBM and tuberculoma was done as per the Ahuja et
al 37criteria and Rajasekhar et al35 respectively . Patients with “definitive” and
“highly probable” TB meningitis as per the criteria were included in the study .
Inclusion Criteria
New cases of TBM, tuberculoma with or without spinal arachnoiditis
whose CSF analysis were negative for fungal infection, malignant cells were
enrolled.
Exclusion Criteria
1) Patients with known serious cardiac disease, renal failure, liver disease,
hematological abnormalities , chronic alcoholism were excluded
from the study.
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2) Presence of secondary immunodeficiency states, such as HIV infection,
AIDS organ transplantation, malignancy, etc.,
3) Currently receiving cytotoxic therapy, or have received it within the last
3 months
4) Pregnancy and lactation
5) Hypersensitivity to antituberculosis drugs
Ethical clearance
The study was cleared by Institutional Ethical Committee (vide letter
Roc.No.39092011).
Clinical evaluation and investigations
Informed consent was obtained from all the patients for participation in
the study. In all of them, a detailed history was taken and a thorough physical
examination was done.
The neurological status was ascertained on admission , level of
sensorium, meningeal signs, focal deficits in the form cranial nerve palsy,
hemiparesis and evidence for raised intracranial pressure was evaluated.
Clinical staging of the illness was done after clinical evaluation . Base line
investigations was done to rule out hematological abnormalities, renal and
hepatic functions.
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Lumbar puncture was performed and the CSF total count, lymphocyte
count,typical cells, protein and sugar levels were estimated at the time of
initial evaluation.CSF was sent for AFB and grams staining . All the CSF
samples were also sent for fungal staining . Repeat CSF examination was
carried out when clinically indicated.
At the time of initial evaluation, plain and contrast-enhanced CT of the
brain was done in all patients with neurological TB ; plain and gadolinium
enhanced MRI of the brain was done if the clinical situation warrants .
During the follow-up visits, imaging investigations and other appropriate
investigations were repeated when clinically indicated.
Treatment and follow-up
All patients with neurological TB were categorized as per the RNTCP
guidelines . New patients with neurological TB treated under Category I,
received 2(H3R3E3Z3)/7(H3R3) (total duration nine months). The continuation
phase of treatment was further extended in selected patients as per the need.
The continuation phase of treatment was further extended in selected patients
as per the need under DOTS cat.I . In patients with TBM, initially,
intravenous dexamethasone was administered according to the body weight as
follows: under 25 kg 8 mg/day; above 25 kg 12 mg/day for 1 to 2 weeks. This
was followed by oral prednisolone in a dosage of 1 to 2 mg/day for children
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and 60 mg/day for adults for 2 to 3 weeks. Thereafter, the oral prednisolone
was gradually tapered off over the next 2 to 3 weeks and then stopped.
In patients with brain tuberculomas , oral prednisolone was
administered in a dosage of 1 to 2 mg/day for children and 60 mg/day for
adults for 3 weeks. Thereafter, the oral prednisolone was gradually tapered
over the next 3 weeks and then stopped.The patients were followed-up on a
monthly basis till they completed the end
Outcome
The treatment outcomes were defined as per the RNTCP guidelines as
“treatment success” (defined as a patient who has either been cured or has
completed treatment) and “default” (patients whose treatment was interrupted
for 2 consecutive months or more). New cases who manifested clinical,
radiological and/or bacteriological deterioration in spite of 5 months of
adequate treatment were termed as “treatment failure”.
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RESULTS
Seventy two patients diagnosed to have neurotuberculosis between Jan.
2012 and dec 2012 were evaluated . Of the 72 patients, 60 patients who
satisfied the inclusion criteria were recruited for the study after obtaining
consent and they were followed up. Twelve patients were excluded from
study due other associated comorbidities like cardiac illness, renal, hepatic
illness , immunocompromised state and haemotological abnormalities.
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1) AGE DISTRIBUTION:
The age distribution of patients enrolled in the study is shown in Table
1. The age group of the enrolled patients were in the range of 14 to 59. The
mean age was 28yrs. Majority of the patients were in the age group 20-29
years (45%).
Table:1
Age Group No. (n=60) %
10 – 19 years 9 15%
20 – 29 years 27 45%
30 – 39 years 9 15%
40 – 49 years 9 15%
50 – 59 years 6 10%
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2) GENDER DISTRIBUTION:
Overall Neuro tuberculosis has male preponderance with a ratio of
Male/Female 65:35.
Table 2 :
Sex n=60 %
Male 39 65%
Female 21 35%
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3) SPECTRUM OF NEURO-TUBERCULOSIS
The various forms of presentation of neurotuberculosis is shown
below in the table 3.
Table 3 :
Spectrum of Neuro tuberculosis N=60
TBM 24
TBM + Tuberculoma 15
Tuberculoma 18
TBM + Arachanoiditis 3
Various forms of Neuro TB:
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4 ) CLINICAL FEATURES :
a) Tuberculous Meningites (N= 24) :
Of the varied manifestations of neurotuberculosis , tuberculous
meningitis (40%) ranks first . The common symptoms on presentation in
patients with TBM in our study were head ache, and fever which are the
mandatory symptoms for diagnosis of TBM according to Ahuja et al criteria 37.
The common signs included altered sensorium, seizures, focal deficits in the
form of haemiparesis, and cranial nerve palsy are depicted below in table 4.
Table 4:
TBM n=24 %
Headache 24 100%
Fever 24 100%
Altered Sensorium 20 83.3%
Focal Deficits 18 75%
Seizures 12 50%
Vision impairment 4 16.66%
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b) Tuberculomas (N=18) :
Tuberculomas (30%) ranks second next to TBM among the
spectrum of illness. The common presenting signs and symptoms of
tuberculoma were seizures followed by head ache , fever and focal deficits.
They are depicted below in table 5
Table 5 :
Tuberculoma n=18 %
Seizures 18 100%
Headache 9 50%
Fever 15 83%
Focal Deficits 2 11.11%
Choreoathetoid movement 1 5.55%
c) TBM & Tuberculoma : (n=15)
The common presentation in patients with TBM and tuberculoma are
head ache, fever , altered sensorium, seizures and focal deficit.
Table : 6
Variable n=15 %
Headache 15 100%
Fever 12 60%
Altered Sensorium 8 53.33%
Seizures 10 66.6%
Focal Deficit 6 40%
Vision impairment 2 13.33%
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d) Spinal Arachanoiditis (N= 3) :
Three cases of TBM with spinal arachanoiditis were enrolled . The
clinical manifestations of the patients were fever, headache, and seizures.
Physical examination revealed neck stiffness, optic atrophy, bilateral VI
cranial nerve palsy and paraplegia.
5) MRC CLINICAL STAGING OF ILLNESS :
a)TBM (with or without tuberculomas / spinal arachonoiditis)
The patients with TBM were staged according to MRC staging
The clinical staging on admission in 42 patients is as follows.
Table 7 :
Stages n=42 %
Stage-1 9 21.4%
Stage-2 15 35.71%
Stage- 3 18 42.85%
Stage 1 Fully Conscious, no paresis
Stage 2 Decreased level of consciousness, no paresis
Stage 3 Deeply comatose with or without dense neurological deficit
35
6) INVESTIGATIONS :
a) Cerebrospinal fluid analysis findings :
The CSF examination findings in 42 patients with TB meningitis are shown in
Table 8. In none of the patients we were able to document AFB in the
CSF .
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CSF findings in patient with TBM (with or without tuberculomas / spinal
arachonoiditis)
Table 8:
Varibles Stage 1( n=9)
Stage 2
(n=15)
Stage 3
(n=18)
Percentage
(n=42)
1) Proteins mg/dl
<100 7 5 2 33.3%
101- 500 2 8 6 38%
> 501 - 2 10 28.5%
2) Cells
<20 (lymphocyte
predominant) 3- 2 5 4.7%
>20 ( lymphocyte
predominant) 3 4 4 38%
>100 (lymphocyte
predominant) 3 9 9 57%
3) Sugar
Normal 7 7 10 57%
< 2/3rds serum
levels 2 8 8 42%
4) AFB stain Negative Negative Negative -
5) Fungal stain Negative Negative Negative -
b) IMAGING
The most common imaging findings in patients with isolated TBM was,
meningeal enhancement (83.33%) followed by hydrocephalus (66.66%), basal
exudates (37.5%) and infarcts (16.6%). In patients with TBM with
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tuberculoma the most common abnormality was meningeal enhancement
(53.33%) followed by basal enhancement (40%), hydrocephalus in (20%) and
infarcts in (20%).In patients with TBM and spinl arachanoiditis all the three
patients had hydrocephalus, meningeal enhancement and basal exudates
Imaging findings in patient with TBM
Variable TBM(n=24)
TBM +
Tuberculoma
(n=15)
TBM + Spinal
arachnoiditis
(n=3)
All patients
(n=42)
Infarct 4 (16.66 %) 3 (20 %) - 7(16.66%))
Hydrocephalus 16 (66.66%) 3 (20%) 3(100) 22(52 .3%)
Meningeal
enhancement
20 (83.33%) 8(53.33%) 3(100) 31 (73.80%)
Basal exudates 9 (37.5%) 6 (40 %) 3(100) 18(42.85%)
Granuloma - 15 ( 100 %) - 15 (35.7%)
Brain Tuberculomas : (n=18)
Table 9
solitary Multiple
Tuberculoma
(N= 18) 12 6
TBM
/TuberculomaStage
(N=15 )
3 12
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Table 10
Location Site N
Supratentorial
Parietal
Temporal
Frontal
Occipital
9
2
6
-
Infratentorial
Brain Stem
Cerebral
Spinal Cord
1
-
-
Among 18 cases of tuberculomas 12 cases had solitary lesions and 6
cases had multiple lesions. In patients who presented with TBM and
tuberculoma (n= 15) multiple tuberculoma was seen in 12 cases and solitary
lesions in 3 cases.
7) TREATMENT n=60 :
a) Medical Management n=54 (90%)
b) Surgical + Medical Management n=6 (10%)
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ENTIRE SPECTRUM OF NEUROTUBERCULOSIS WITH THE
MODALITY OF MANGEMENT
All the 60 patients enrolled in this study were new cases of tuberculosis
and hence entitled to receive Cat.I ATT and steroids according to the
prescribed protocol.
CAT.I ATT
Seriously ill IP - 2 H3 R3 Z3 E3
Extra pulmonary MP - (7-10) H3 R3
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Table 11
Type of
Surgical Intervention n=6
VP Shunt 5
Drainage of abscess 1
8 ) FOLLOW-UP
Follow-up of these patients were made monthly and they were
evaluated for clinical, radiological and bacteriological / CSF analysis for
subsequent improvement / deterioration during the follow-up.
Treatment was initiated in all the 60 patients of neurotuberculosis with
Cat. I ATT, and steroids ( i.v decadron ) in the dose of 0.4 mg per Kg body
weight for 1 week 0.3 mg/Kg body weight in second week, 0.2 mg/kg body
weight in the third week , 0.1 mg/kg body weight in the fourth week . At the
end of 4 weeks patients were switched over to oral prednisolone at the dose
of 1 mg/kg body weight and the dose gradually tapered and stopped in 4
weeks.
Among the 60 patients followed up 6 patients lost follow up ( 4 cases
of TBM +/- Tuberculoma +/- Arachnoiditis and 2 cases of isolated
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tuberculoma) and four cases defaulted drugs. (2 cases of TBM and 2 cases
of tuberculoma).
Among the 50 patient who were regularly followed up, 6 patients
level of sensorium worsened (2 patients progressively worsened since
admission) . Subsequent imaging in these patients showed worsening of the
grade of hydrocephalus requiring VP shunt in 5 patients . On subsequent
follow up these patients developed shunt dysfunction, shunt infection, increase
in the size of the tuberculomas and 2 patients out of 5 succumbed to death in
the 3 rd month of treatment. In addition these patients required anti edema
measures. Two patients showed improvement and they required 12 months of
ATT and they finally completed treatment successfully. In one patient there
was tuberculous abscess formation and drainage of the abscess was done
through a frontal burr hole. Later this patient developed bilateral hemorrhagic
infarct due cerebral venous sinus thrombosis at 7th month of ATT,
communicating hydrocephalus with features of raised intracranial pressure .
Finally this patient was considered to be a treatment failure case in view of
occurrence clinical and radiological worsening after 7 months of ATT.
In 18 cases of tuberculoma , 12 were solitary lesions and a minimal
regression of the lesions were noted . In 6 cases with multiple lesions 2 cases
defaulted treatment , 2 cases lost follow up and in the remaining 2 patients
there was an worsening of symptoms with increasing frequency of seizures
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and imaging showed increase in the size of lesions and occurrence of new
lesions. These case were given 12 months of ATT. These cases were labeled as
treatment failure .
Adverse drug reactions
Two patients (3.3%) in our study developed antituberculosis drug-
induced hepatotoxicity. The first-line drugs were stopped and the patient was
treated with streptomycin, and ethambutol till the liver functions normalized.
The first-line drugs could be successfully reintroduced in both the patients .
9) DURATION OF TREATMENT WITH ATT :
a) TBM (with or without tuberculomas / spinal arachonoiditis) : N= 42
Table 12:
Duration Of
ATT
Stage 1
(n=9)
Stage 2
(n=15)
Stage3
(n=18)
9 Months 9 12 -
10 Months - - -
12 Months - - 13
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10 )COMPLICATIONS
Table :13
Variables Stage 1
n=9
Stage 2
n=15
Stage 3
n=18 Percentage
Focal deficit - 12 18 71.42%
Hydrocephalus - 7 15 52.38%
Tuberculomas (new lesions/
enlargement of existing
lesions)
2 5 16.66%
Tuberculous abscess - 1 2.38%
Opticochiasmatic
Arachanoiditis - 2 6 20%
SIADH 3 7.14%
Vascular infarcts
- 3 4 16.66%
Spinal Arachanoiditis
- 3 - 7.14%
Patients who presented with isolated tuberculomas (n= 18 ) 12 had
solitary and 6 had multiple lesions. Among the 14 patients who completed
follow up showed 2 devoloped new lesions , and there was increase in the
size of the preexisting lesions in 2 patients , the outcome of treatment in these
two patients was treatment failure .In the remainng 12 patients radiological
resolution was observed in only 6 patients.
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11) DEFINITIONS OF OUTCOMES
Outcomes Definition
Treatment Success Defined as a patient who has been entirely cured or has
completely healed.
Default Patients whose treatment was interrupted for 2
consecutive months.
Treatment Failure New cases who manifest clinical, radiological and
bacteriological deterioration inspite of 5 months of
adequate treatment.
12 ) TREATMENT OUTCOME
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a) Treatment outcome in 42 patients with TBM (with or without brain
and spinal tuberculomas; spinal arachnoiditis) and 18 patients
with brain tuberculomas
Treatment outcome
TBM
(n=42)
No. (%)
Brain tuberculomas
(n=18)
No. (%)
Successful outcome
(completed treatment) 33 (78.8%) 12 (66.66%)
Treatment failure 01 (2.38%) 02 (11.11%)
Defaulters 02 (4.76%) 02 (11.11%)
Death 02 (4.76%) 00 (0)
Lost to follow-up 04 (9.52%)) 02 (11.11%)
b) Analysis of the outcome in the entire spectrum of neurotuberculosis
Table 14
Total n=60 %
Treatment Completed n=45 75%
Lost follow-up n=6 10%
Defaulted N=4 6.66%
Death n=2 3.3%
Failure N=5 8.33%
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13) Correlation of Treatment Outcomes With Clinical Stage In Tbm
(with or without brain tuberculoma and spinal archanoiditis):
Table 15
Variable Total
n=42
Stage 1
(n=9)
Stage 2
(n=15)
Stage3
(n=18)
Treatment
Completed 33 9
12 12
Lost follow-up 4 - 3 1
Defaulted 2 - 2
Death 2 - - 2
Failure 1 - 1
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Brain Stem Tuberculomas showing minimal change in the size of
the lesion after completion of 9 months of
ATT – RNTCP CAT 1 DRUGS
FIG 1
FIG 2
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Sequential Images In a girl Who Presented With TBM And
Hydrocephalus
Underwent VP Shunt And Subsequent Shunt Related Complications
1) Hydrocephalus 2) Right VP Shunt
3) Shunt Revision 4) New Lesions
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Multiple Conglomerulte Lesions With Meningeal Enhancement
a) Coronal view
b) Saggital view
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Reduction In The Size Of The Lesions And Occurrence Of New Lesions
After 9 Months Of Treatment
Contrast enhancement seen in the optochiasmatic region
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DISCUSSION
The incidence of tuberculous infection in India is very high
contributing to one fifths of the global burden of tuberculosis. Our institute is
is tertiary care centre catering to the health needs of the Chennai and
Southern India . We have a RNTCP unit functioning in our hospital . Cases
were diagnosed based on clinical examination and available investigationas.
Highly propable cases of neurotuberculosis were registered under DOTS and
drugs were issued and the patients were subsequently followed up at monthly
intervals.
Demographic Factors
Sixty patients of new cases of neurotuberculosis were registered and
followed up prospectively. The demographic profile of the patients registered
was that the affected were in the age group of 10 to 59 patients. Majority of the
affected were in the age group 20- 29.There is a male predominance in the
distribution of the illness, whereas WHO reports a equal distribution among
males and females. the sex distribution males are more affected than the
females.
Clinical Manifestations
The clinical manifestation of our patients were protean . Patients
diagnosed as highly propable cases of tuberculous meningit( according to
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Ahula et 37 criteria ) all had the mandatory clinical features of fever and head
ache of more than 2 weeks duration . This is consistent with the study done by
Thwaites et al 48 . Patients were reffered to us with a prolonged duration of
fever ranging from 2 weeks to 3 months being treated by the primary care
physicians after evaluation for causes of fever. Majority of these patients did
not have a system localization at the beginning of the fever and on
investigating were found to be positive for widal and leptospirosis and was
treated accordingly. The occurrence of vague symptoms and lack of
significant signs and symptoms pertaining to nervous system leads to the
fallacy in the diagnosis. Patients on arriving at our hospital had the florid
symptoms and signs pertaining to nervous system without much difficulty in
diagnosis. Lack awareness of this life threatning illness is another cause for
lack of early diagnosis and late referral 45. Patients are referred here after
occurrence of altered sensorium , focal defecits , seizures and visual
impairment .
All patients diagnosed to have tuberculoma presented with seizures.
Seizures was more common in tuberculoma than the other form of
neurotuberculosis spectrum.On detail enquiry about the seimiology of the
seizures the predominant seizure type was focal seizures, followed by focal
with secondary generalisations. Maduranth has reported seizures to be the
predominant manifestation in patients with tuberculoma 15 . Arseni et al 43
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has reported seizures in 85 % of patients with tuberculoma . Gulati et al 44
have reported that the commest cause of focal seizure was tuberculoma.
Regarding the history of past occurrence of pulmonary tuberculosis
none of our patients had pulmonary tuberculosis .A prior history of
tuberculosis is present in approximately 10% of adult patients with tuberculous
meningitis .12,13,14
Michael swash et al41 have reported a past history of tuberculosis in
about 50 % of our patients . This must be due to our rigid inclusion criteria
which included only new cases of tuberculosis. Focal deficits were in the
form of hemiparesis, hemiplegia, and cranial nerve palsies .
Our study reports vision impairment in 14% of the entire spectrum of
neurotuberculosis .The range of vision impairment ranges from legal
blindness to functional impairment of vision.None of them at presentation had
vol;untered this problem. Sinhaet al46 reported that 27% of TBM patients had
decreased vision due to optochiasmatic arachanoidtis (OCA). Aaron et al.47
report a figure of 14% with OCA . In view of occurrence of this problem in
significant portion of the patients , it has to be anticipated though this
problem is not volunteered. Choreothetoid movements were the intial
presentation of tuberculoma in 5% of patients. Alarcon et al has also
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documented choreoathetoid movement to be the presenting manifestation of
tuberculoma49 .
Spectrum of Neurotuberculosis
The spectrum of neurotuberculosis includes TBM (with or without
tuberculoma and spinal arachanoiditis ) and isolated tuberculoma. In our study
65 % of the spectrum comprises of TBM (with or without associated
tuberculoma). Two studies have documented 70 to 80% of cases of neuro
tuberculosis spectrum to be TBM (with or without tuberculoma/
arachanoiditis)56 .
Staging of the illness:
Clinical staging of the illness as per MRC grading done showed that
majority of our patients were in stage 2 (35%) and 3(43 %) of illness at
presentation. In tuberculous meningitis the only and single most important
physician governed factor irrespective of the treatment regimen which
decides about the outcome of the illness is the clinical stage of the illness.
Zahra Ahmadinejad hs documented 14.6% in stage I ,34.4% in stage II and
51% in stage III TBM 50 . They found that age, and the clinical stage of the
illness 5 were prognostic factors which decided the outcome
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Investigatons:
CSF analysis
CSF Protein estimation at presentation in patients with TBM ( with or
without tuberculoma / archanoiditis ) reveled elevated proteins. The levels
being 33% had mild elevation (<100 mg/dl), 38% had moderate elevation (
101 – 500) and
28 % had severe elevation (> 501) . Eighty eight percentage of
patients who presented in stage 2 and stage 3 of illness had moderate to
severe elevation of proteins . Ths shows that those who presented in advanced
stages had higher levels of CSF proteins 52 53. CSF sugars were normal in
55% and reduced less than 2/3rds in 45% 0f patients .There was no
correlation between the severity of the illness and the CSF sugar levels.In
contrary Hosoglo has found a correlation between severity of the illness and
CSF sugar levels52 . Seventy six percent of the patients showed tuberculous
range of lymphocytic pleocytosis . In our study we were not able to
document the microorganism in the biologicl fluid. Definitive diagnosis of
tuberculous meningitis depends upon the detection of the tubercle bacilli in
the CSF, either by smear examination or by bacterial culture. It has been
claimed that if large volumes of CSF are carefully examined the organism can
be found in over 90% of centrifuged CSF specimens53 . Bacteriological
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diagnosis was made in 107 of 132 adults with clinically suspected tuberulous
meningitis53.
IMAGING
Our study revealed the most common finding on imaging in patients
with TBM (with or without tuberculoma/ archnoiditis ) to be meningeal
enhancement (75%), hydrocephalus (52%), basal exudates (42%) and infarcts
(7%) and granulomas ( 35%). Two studies have revealed basal enhancement
of the meninges (particularly in the perimesencephalic cisterns ),
hydrocephalus, infarction edema often located periventricularly, and mass
lesions due to associated tuberculoma or tuberculous abscess, to be imaging
abnormlties in descending order2627. A study revealed that hydrocephalus
was the single most common abnormality seen by CT scan in 52 % to 80% of
patients with tuberculous meningitis . Goyal et al studies revealed
enhancement of the meninges is seen in approximately 60% of patients with
tuberculous meningitis which may be localized or diffuse 31 . Two large
community based studies analysed the imaging findings in patients with TBM
and found that Hydrocephalus was found in 78% , basal enhancement was
found in 38% infarcts in 15-30% and tuberculomas in 5-10% of the patients.
The common site of location of these tuberculomas are parietal and
frontal lobe . Multple tuberculoms re more common than solitary
tuberculoma. . Infratentorial location of tuberculomas are less frequent . . In
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our study we have documented a single case of brain stem tuberculoma in
adolescent girl who presented with choreoathetotic movements . The
distinctive MRI features of non-caseating granulomas, caseating granulomas
with solid or liquid centre was made out 36. . In our study 14% reported
visual impairment but 20% had evidence of enhancement in the
optochiasmatic region.
Surgical Intervention
In our study only 6 out of 60 patients required surgical intervention. The
procedures done on these patients were ventriculoperitoneal shunt and
drainage of the abcess. VP shunt was done in patients with TBM and
hydrocephalus. Patients with TBM and hydrocephalus was staged from 1 – 4
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. Of the 5 patients who underwent the shunting procedure 2 patients were in
stage 2 of illness and 3 were in stage 3 of the illness. The outcome of the
procedure was that patients who underwent the shunting procedure in stage 3
illness succumbed to lot of complications like shunt dysfunction , shunt
infection requiring shunt revision . Regarding outcome of the patients treated
with surgical intervention out of 6 patients 2 died Four patients were labeled
as treatment failure , as they continued to develop worsening of clinical
features apart from shunt related complications.
The South African study group Lamprect et al had suggested that
surgery be reserved for those patients in stage 2 and 3 with obstructive
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hydrocephalus rather than those with communicating hydrocephalus.Medical
management with mannitol , acetazolamide was adviced for patients in stage 2
with communicating hydrocephalus. Bagavathi et al 48 has reported mortality
in 3 out of 7 patients undergoing the shunt procedure. Only 4 out of 9 payients
treated by Upthaya et49 improved following surgery and the rest died at
different times following surgery. The mortality rate of those who underwent
surgery was 10.7 to 57 % in those with altered sensorium and only 12.5 % in
those with normal sensorium.
Outcome
Seventy five percent of those treated with RNTCP regimen were
rendered asymptomatic after completion of treatment . Treatment failure
was 8.33% and death rate was 3.33 percent . In 16.66% we lost follow up
as patients did not turn up for their monthly follow up.
The goal of RNTCP 57 is to achieve a cure rate of 85% in newly
diagnosed sputum positive pulmonary tuberculosis and to improve the case
detection rate to 70% after the first said goal is achieved . RNTCP focuses
mainly on pulmonary tuberculosis and the same targets are maintained for
extra pulmonary tuberculosis To document a cure , we need to document the
presence of microorganism in the biological fluid and also its clearance after
completion of treatment. We were not able to document the microorganism in
any of our cases . Diagnosis was done based on a prevalidated criteria and we
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were able to see clinical and radiological improvement after treatment which
is defined as treatment completed or successful treatment . Though we were
not able to document a cure of 85 percent, we were able to demonstrate a
successful treatment in 75% of the patients which is close to the target.
In a study from Kerala (n=32) done by Venugopalet al52 who registered
32 cases of neuro tuberculosis under DOTS regimen in their study, of whom
29 completed treatment and all were asymptomatic at the end of treatment
(85%). All patients in their study were given 9 months intermittent regimen as
per RNTCP guidelines. Five patients (14%) died during treatment. Their result
showed that intermittent short course chemotherapy under field program
conditions was efficient in curing neuro tuberculosis . DOTS to be effective in
TBM (83%). Inspite of choosing cases carefully with a predefined validated
criteria for diagnosis and meticulously following up, the the target fixed
by the RNTCP could not be achieved . Studies published from India 59 60 61
documents mortality up to 75% and sequelae up to 85%. In our study
mortality of 3.33 percent has been documented . The difference in the
relative success of treatment of TBM when compared to tuberculoma reflects
that the basic immune mediated pathogenetic mechanism play a role in
occurrence of new lesions and enlargement of the existing lesions rather than
persistence of the infective organism .
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CONCLUSION
1) The spectrum of illness of neurotuberculosis affects younger individuals
in the age group of 20 to 29 and has a male preponderance.
2) The most common type of presentation of neurotuberculosis is
tuberculous meningitis and the common symptom is fever and head
ache. The most common manifestation of tuberculoma is seizures.
3) TBM patients present in the advanced stage ( stage 2 and stage 3) of
the illness.
4) The most common complication of TBM is hydrocephalus and the
most devastating complication of neurotuberculosis is visual impairment
due to optochiasmatic arachanoiditis .
5) CSF proteins correlated with clinical severity of illness and it can used
to prognosticate the adverse outcome.
6) Twenty two percentage of those who had hydrocephalus underwent
surgical intervention like ventriculoperitonel shunting . The outcome of
surgical intervention is disappointing with deaths occurring in one third,
treatment failure in one third , and one third left back with severe
neurological sequlae.
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7) The outcome of mangement with the standard RNTCP DOTS regimen
was that a success rate (treatment completed ) of 75%, default rate of
6.6%, mortality rate of 3.3% was obtained . The target fixed by the
RNTCP is to achieve a cure rate of 85%.We were able to document a
successful completion of treatment in 75% which is close to the target
fixed by RNTCP. The default rate is 6.6% which quite negligible when
compared to the unsupervised therapy which has a default rate of 50%.
8) Early diagnosis of neurological TB is important because, the timing of
initiation of antituberculosis treatment is the most important variable for
predicting the outcome in these patients .A high index of clinical
suspicion coupled with a battery of imaging and CSF laboratory
investigations are required to confirm the diagnosis as it is
exceptionally difficult to ascertain histopathological / microbiological
proof.
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PROFORMA
1. Name : Age / Sex :
2. OP / IP :
3. Address :
4. Clinical Features : Signs & Symptoms
• Headache
• Fever
• Vomiting
• Seizures
• Focal Deficit
• Pappiledema
• Visual Impairment
• Meningeal Signs
5. Clinical Staging of Illness (MRC)
• Stage I :
• Stage II :
• Stage III :
6. Investigations
• CBC
• RFT
• LFT
• Chest X-Ray
• HIV
• CT / MRI (Brain)
• CSF
o Cells
o Proteins
o Gram Stain
o AFB Stain
o Fungal Stain
8. Treatment
• Medical – ATT Category 1 Duration of Months
9 Months
10 Months
12 Months
• Surgical
9. Followup : Assessment
• Clinical
• Biochemical
• Radiological
10. Outcome
• Treatment Successful
• Failure
• Defaulter
• Death
• Lost follow up
FEVER
HEAD 
ACHE
ALT.SENS
ORIUM
SEIZURES DEFICIT
MENINGEAL 
SIGNS
VISION CT BRAIN MRI brain CSF cells
PROTEINS
mg/dl
SUGAR 
mg/dl
AFB
SUDHAKAR 17/M TBM/TUBER I NO YES No GTCS No Yes NORMAL Normal ME Few lymph. 78 54 Nil 9 Nil SUCCESS
MD. KHAN 22/m TUBERCULOMA - NO YES NO FOCAL NO NO NORMAL
hypodens
e
B E NIL NIL NIL NIL 9 NIL SUCCESS
ANITHA 27/F TBM/TUBERCULOMA I NO YES NO FOCAL NO NO NORMAL NORMAL B E NIL 125 24 NIL 12 NIL SUCCESS
SUKUMAR 24/M TBM/TUBERCULOMA II YES YES YES GTCS NO NO NORMAL ME ME 12 LYMPH 43 45 NIL 9 NIL SUCCESS
KUTTIAMMA 35/ F TBM/TUBERCULOMA III YES YES YES GTCS YES YES  VI ME BE/HY 46 LYMPH 480 56 NIL 9 NIL SUCCESS
KANNAN 48/M TBM III YES YES YES FOCAL YES YES NORMAL NORMAL HY 23 LYMPH 120 23 NIL 12 VPSHUNT FAILURE
PARVATHY 32/f TBM III YES YES YES GTCS YES YES VI I/BE/HY E/I/H 56 LYMPH 1.2 12 NIL 3 VP SHUNT DEATH
KATHARINA                  21/M TBM I YES YES YES GTCS YES YES NORMAL NORMAL ME/HY NIL 54 43 NIL 9 NIL SUCCESS
SUDALAI 22/m TBM/TUBE II YES YES YES NO NO YES NORML H/ME H/ME 48 L 76 32 NIL 9 NIL SUCCESS
AYUBKHAN 19/m TBM III YES YES YES GTCS YES YES NORMAL H/ME H/ME 12 LYMPH 65 34 NIL 9 NIL SUCCESS
RUDRAKUMAR      25/M TBM III YES YES YES GTCS YES YES NORMAL H ME/H 18 L 100 23 NIL 10 nil success
BAKIYAVATHY 37/f
spinal aracha      -                                 
-
III NO no no YES YES YES NORMAL ara arac 76L 65 24 NIL 9 NIL SUCCESS
KARTHICK 21/m TBM III YES YES YES NO YES YES ME ME be/hy 67L 300 23 NIL 12 NIL
LOST 
FOLLOW
LAKSHMI 25/F TBM III YES YES YES GTCS YES YES
IMPAIRDE              
H/I/ENHA            
ME/H 87L 1.5GMS 34 NIL 4 VPSHUNT DEATH
SURESH 31/M TBM II YES YES YES FOCAL YES YES H NORMAL H OBS. 76L 150 12 NIL 12 VPSHUNT FAILURE
RAVEENDRA        30/M TUBERCULOMA I NO no NO FOCAL NO NORMAL NORMAL G FG NIL NIL NIL NIL 9 NIL SUCCESS
PREMA NATAR      50/F TBM/TUBE II NO YES NO FOCAL NO NORMAL NORMAL FP TUBER G 23L 450 23 NIL 12 NIL SUCCESS
SUKUMAR 24/m TBM III YES YES YES GTCS YES YES IMPAIRED OCA BE/OCA/H 78L 600 14 NIL 9 NIL SUCCESS
AJITHA 51/f F TUBER - NO NO NO FOCAL NO NORMAL NORMAL F TUBER FT NIL NIL NIL NIL 9 NIL SUCCESS
GOVINDHAN 15/m TBM II YES YES YES NO YES YES NORML ME ME 21 L 67 32 NIL 9 NIL SUCCESS
VEERAMMA 20/f TBM/TUBER II YES YES YES FOCAL NO YES NORMAL NORML ME/G 34 L 87 32 NIL 10 NIL SUCCESS
SARITHA 29/f TBM/TUBER II YES YES NO GTCS YES YES NORMAL NORMAL ME 23 L 94 23 NIL 9 NIL SUCCESS
AYYANAR 28/m p tuber - YES yes NO FOCAL YES NORMAL NORMAL NORMAL PG NIL NIL NIL NIL 12 NIL DEFAULT
BANU 14/f TBM II YES YES YES YES YES YES NORMAL NORMAL ME FEW 87 34 NIL 9 NIL SUCCESS
CHOKKU 33/m TBM/TUBER II YES YES YES FOCAL YES YES VI ME ME 23  L 87 32 NIL 10 NIL SUCCESS
RAVI 28/m TBM II YES YES YES NO YES YES NORMAL BE normal 23    L 98 21 NIL 12 NIL SUCCESS
RANI 24/f f tuber - YES yes NO FOCAL YES NORMAL NORMAL FG FG NIL NIL NIL NIL 12 NIL SUCCESS
CHINNAPPA 38/m TBM II YES YES YES NO YES YES NORML NORML BE FEW CELLS 65 32 NIL 12 NIL SUCCESS
ELANGO 24/m s arahano III YES YES No YES YES NORMAL NORMAL VI arac 56 43 26 NIL 10 NIL DEFAULT
SUBBSMA 39/f TBM III YES YES YES YES YES YES IMPAIR OCA oca/be 28  L 643 11 NIL 9 NIL SUCCESS
STAGE
MASTERCHART
ATT 
DURATIO
N
SURGERY OUTCOME
SYMPTOMS & SIGNS IMAGING CSF ANALYSIS
NAME AGE/SEX DIAGNOSIS
FEVER
HEAD 
ACHE
ALT.SENS
ORIUM
SEIZURES DEFICIT
MENINGEAL 
SIGNS
VISION CT BRAIN MRI brain CSF cells
PROTEINS
mg/dl
SUGAR 
mg/dl
AFB
FARIQ 27/M TBM III YES YES YES NO YES YES IMPAIR OCA oca/be/ 23  L 345 23 NIL 12 VPSHUNT SUCCESS
THARANI 28/f fp tuber YES no NO FOCAL YES NORMAL NORMAL f g NIL NIL NIL NIL 9 NIL LOST FOLLOW
RAJU 46/m TBM I YES YES NO NO NO YES NORMAL normal 23 L 52 NIL NIL 10 NIL SUCCESS
RAVI 19/m TBM III YES YES YES YES YES YES 56 L 230 12 NIL 9 NIL DEFAULT
KANNAGI 25/f TBM III YES YES YES YES YES YES IMPAIRE OCA oca/i/hydr 32 L 176 32 NIL 10 VPSHUNT SUCCESS
SHANKAR 47/m PF TUBER NO yes NO FOCAL YES NORMAL NORMAL pf g NIL N NIL NIL 9 NIL FAILURE
THIRUMAL 42/m TBM I YES YES NO NO NO YES NORMAL normal FEW CE 53 32 NIL 10 NIL SUCCESS
SATISH 25/m TUBERCUL YES no NO GTCS YES NORMAL NORMAL f g NIL NIL NIL NIL 9 NIL LOST FOLLOW
KRISHANA 46/m TBM I YES YES NO NO NO YES NORMAL normal 10 L 49 NIL NIL 10 NIL SUCCESS
PAUL 23/m TUBERCUL NO yes NO FOCAL YES NORMAL NORMAL FG FG NIL N NIL NIL 9 NIL SUCCESS
MANGAMA 28/f TBM/TUB I YES YES NO FOCAL NO YES NORMAL G G 18  L 49 21 NIL 10 NIL SUCCESS
JOE 28/m TUBERCUL YES no NO FOCAL YES NORMAL NORMAL G G NIL N NIL NIL 9 NIL LOSTFOLLOW
RAJA 47/m TBM I YES YES NO NO NO YES NORMAL NORMAL normal 13   L 51 21 NIL 10 NIL SUCCESS
HELEN 41/f TBM/TUB III YES YES YES NO YES YES VI H I/E/H 34  L 180 12 NIL 9 NIL SUCCESS
PREMA NATAR     50/F TUBERCUL YES yes NO FOCAL YES NORMAL NORMAL FG FG NIL N NIL NIL 10 NIL SUCCESS
DHARANI 25/f arachano NO NO YES NO YES NORMAL NORMAL ME sp ara 56L 67 12 Nil 9 NIL SUCCESS
MURUGAN 18/m brain stem t no no NO NO YES NO NORMAL G granu 14 L 76 21 NIL 10 NIL SUCCESS
RAJI 47/m TBM III YES YES YES NO YES YES VI H ME/H 32L 198 12 NIL 9 NIL SUCCESS
SUNDAR 28/m TBM/TUB II YES YES NO NO NO YES VI H ME/BE/H 43 L 98 21 NIL 10 NIL SUCCESS
KATHIR 48/m P TUBERCULOMA YES yes NO FOCAL YES NORMAL NORMAL PG PG NIL NIL NIL NIL 10 NIL SUCCESS
ANTONY 52/m TBM II YES YES YES NO YES YES H ME/H 12   L 98 21 NIL 9 NIL SUCCESS
PANDI 23/m FPTUBERCULOMA NO yes NO FOCAL YES NORMAL NORMAL FG FG NIL NIL NIL NIL 10 NIL SUCCESS
PONNI 53/f TBM/TUBE III YES YES YES NO YES NO VI H ME/BE/H 60 L 309 14 NIL 9 NIL
LOST 
FOLLOW
MANIMAL 18/f TUBERCULOMA NO no NO GTCS YES NORMAL NORMAL G G NIL NIL NIL NIL 10 NIL SUCCESS
MUNISAMI 53/m TBM/TUB II YES YES YES FOCAL NO NO NORMAL H HYDRO 10 L 65 12 NIL 10 NIL SUCCESS
PANCHALAI 52/f TUBERCULOMA NO no NO FOCAL YES NORMAL NORMAL FG FG NIL NIL NIL NIL 9 NIL DEFAULT
VENKATAMA 26/f TBM II YES YES YES NO YES YES NORMAL H HYDRO 34 L 98 14 NIL 10 NIL SUCCESS
PAZANI 18/m TUBERCULO III YES no YES GTCS YES NORMAL NORMAL H ME/H 34 L 123 15 NIL 9 NIL
LOST 
FOLLOW
MEGALA 27/m TBM/TUBE III YES YES YES NO YES NO NORML H H 34 L 243 19 NIL 10 NIL SUCCESS
NISHA 19/f TUBERCULOMA NO no NO GTCS YES NORMAL NORMAL FG FG NIL NIL NIL NIL 9 NIL SUCCESS
ATT 
DURATIO
N
MASTERCHART
NAME AGE/SEX DIAGNOSIS STAGE SURGERY OUTCOME
SYMPTOMS & SIGNS IMAGING CSF ANALYSIS
KEY FOR MASTER CHART
ME - Meningeal Enhancement
BE - Basal Exudates
H - Hydrocephalus
L - Lymphocytes
G - Granuloma
P - Parietal
F - Frontal
VI - Visually Impaired
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